Professional Documents
Culture Documents
artemisinin
produc+on
Technology
for
biobased
products
Chris
Paddon,
Ph.D.,
Principal
Scien4st,
Amyris
Inc.
Semi-Synthe+c
Artemisinin
BIOLDING
investment
O
O O
H H
O
O
2004
WHO
recommends
Artemisinin-based
Combi-
na1on
Therapy
(ACT)
Source:
WHO
1000
800
600
400
200
0
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Year
Periodic
supply
shortages
(e.g.
2009)
Hard
for
ACT
manufacturers
to
plan
produc1on
Copyright 2014 Amyris, Inc. All rights reserved
Semi-Synthe+c
Artemisinin
produc+on
uses
fermenta+on
and
chemistry
to
stabilize
supply
Semisynthe1c
method
Fermenta1on
&
Photochemistry
About
3
months
from
lab
to
ACT
Agricultural
method
Cul1va1on
and
extrac1on
About
10
months
from
seed
to
ACT
Isoprene
G6P
FDP
G3P
PEP
DXP
idi
PYR
IPP
DMAP
ispA
AcCoA
Amorphadiene
Mevalonate
FPP
OAA
Pathway
TCA
Cycle
CIT
Amorphadiene
MAL
Synthase
(ADS)
Copyright 2014 Amyris, Inc. All rights reserved
Produc+on
of
25g/L
Amorphadiene
in
E.
coli
30
run1
run2
25
g/L
target
Amorphadiene
(g/l)
20 run3
10
0
0
50
100
150
200
Time
(h)
Amorphadiene
H Biological
oxida1on
Synthe1c
chemistry
Artemisinic
Acid
H
HO
O
H
O
O
H
Artemisinin
H O
O
H
Yeast
Eukaryo1c
system
Simple
to
engineer
Industrially
scalable
(Beer,
wine,
alcohol)
Can
express
cytochrome
P450
enzymes
80
0
ADS
1xtHMG
P(MET3)-ERG
UPC2-1
2x
tHMG
FPPS
Gene+c
modica+on
From
Ro
et
al
Nature
(2006)
convert
it
to
artemisinin?
Copyright 2014 Amyris, Inc. All rights reserved
See
you
next
unit